Aestyve®

FORM



The science of form.

Aestyve aesthetics, beginning with material.

ALPHA / BETA / GAMMA

Beyond the surface.

Beyond appearance, into material structure.

Composition, structure and properties define the Aestyve collection. Three product lines, supported by manufacturer technical data.

01
MATERIAL

02
STRUCTURE

03
PERFORMANCE

Meet the collection.



ALPHA

Alpha



BETA

Beta



GAMMA

Gamma

What is within.



MATERIAL


Cross-linked HA
and lidocaine HCl
in an HA gel.

24	1.1	0.3
mg/mL	mL	%
HA concentration	Syringe volume	Lidocaine HCl

P01 | Lidocaine HCl 3 mg/mL = 0.3%. Composition and volume follow AESTYVE carton labels.

Structure by design.


Microstructure through low-temperature crosslinking.



SAMPLE A

HBCT

Manufacturer data describe a three-dimensional HA gel through the HBCT process.



HBCT HA


SEM

Original SEM images show the morphology of the microstructure.

T01, p.4 | Magnification, preparation and replicates are unspecified. Images alone do not establish clinical superiority.

A spectrum of elasticity.

Storage modulus | Manufacturer formulation ranges




T01, p.9; T02 | Reported ranges, not means or error bars. Temperature, frequency, strain and replicates are unspecified.

Consistency in motion.

13.62 N

Deep
27G needle

AVERAGE EXTRUSION FORCE



T01, p.6; T02 | Deep formulation, 27G needle. Mean extrusion force: 13.62 N. Curve reproduced from manufacturer data.

Held together.



COHESIVENESS

Cohesiveness testing examines gel interaction. Reported test lengths by formulation.

2.4 cm	2.1 cm	2.0 cm
FINE	**DEEP**	**VOLUME**

T02 | Test lengths: 2.4, 2.1, 2.0 cm. Speed, temperature and replicates are unspecified. Gel photograph illustrates texture, not test results.

Purity, measured.

HA raw-material criteria

Bacterial endotoxins	≤0.020 IU/mg
Microbial contamination	≤5 CFU/g

Two stages, two weeks | Product test results

0 ppm


Residual BDDE | Reported

<1.0 ppm

Heavy metals | Reported

T01, p.5 | Product test table covers 1.1 and 10.0 mL. Raw-material criteria are separate. Detection limit unspecified; 0 ppm does not establish absolute absence.

Observed over time.



24

WEEKS

KBIOHealth Animal Center | 2020.09.18-2021.03.23

T01, p.4; T02 | Animal-study MRI of a low-elasticity formulation. Observation times do not establish human duration, retention or safety.

The collection, in detail.

Specification	ALPHA	BETA	GAMMA
HA concentration	24 mg/mL	24 mg/mL	24 mg/mL
Lidocaine HCl	3 mg/mL	3 mg/mL	3 mg/mL
Syringe volume	1.1 mL	1.1 mL	1.1 mL
Needle	30G x 2	27G x 1	25G x 1
Cannula	-	25G x 1	23G x 1

STORAGE

Store at 2-25°C, away from light and moisture.
Refer to the current label for expiry and lot number.

P01: AESTYVE packaging. T01: Manufacturer technical data, 2026.01.26, pp.4-6, 9. T02: Manufacturer brochure, p.1. Technical sources, not peer-reviewed studies.

Aestyve®

Material.
Structure.
Form.

---

www.aestyve.com

info@aestyve.com

HA FILLER / ENGLISH EDITION